Pancreatic Cancer Research

ResearcherFudan UniversityActive in the last 2 years

Lili Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4108-893X; OpenAlex author ID A5100775197. Sources: OpenAlex.

Their work

Papers
6 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 6

  1. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  2. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  3. Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. First author DOI 10.3233/ch-190786↗
  4. Negative regulation between the expression levels of receptor for hyaluronic acid-mediated motility and hyaluronan leads to cell migration in pancreatic cancer. Co-author DOI 10.3892/ol.2020.12060↗
  5. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.01543↗
  6. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xi Guo · 4 shared papers, 2018–2024 · strength 0.48
  2. Yuhong Zhou · 4 shared papers, 2018–2023 · strength 0.43
  3. Yaolin Xu · 3 shared papers, 2018–2024 · strength 0.40
  4. Dansong Wang · 3 shared papers, 2018–2024 · strength 0.40
  5. Wenchuan Wu · 3 shared papers, 2018–2024 · strength 0.40
  6. Yue Fan · 3 shared papers, 2018–2023 · strength 0.33
  7. Wenhui Lou · 2 shared papers, 2023–2024 · strength 0.32
  8. Yuan Ji · 2 shared papers, 2019–2024 · strength 0.24
  9. Lie Yao · 1 shared paper, 2024 · strength 0.16
  10. Xuefeng Xu · 1 shared paper, 2024 · strength 0.16
  11. Yefei Rong · 1 shared paper, 2024 · strength 0.16
  12. Wenquan Wang · 1 shared paper, 2024 · strength 0.16
  13. Liang Liu · 1 shared paper, 2024 · strength 0.16
  14. Dayong Jin · 1 shared paper, 2024 · strength 0.16
  15. Yuhong Zhou · 1 shared paper, 2024 · strength 0.16
  16. Tiantao Kuang · 1 shared paper, 2024 · strength 0.16
  17. Jing Liu · 1 shared paper, 2024 · strength 0.16
  18. Jun Zhang · 1 shared paper, 2024 · strength 0.16
  19. Deliang Fu · 1 shared paper, 2024 · strength 0.16
  20. Xiaowei Liu · 1 shared paper, 2024 · strength 0.16
  21. Qi Zhang · 1 shared paper, 2020 · strength 0.13
  22. Wen‐Ping Wang · 1 shared paper, 2020 · strength 0.13
  23. Yijie Qiu · 1 shared paper, 2020 · strength 0.13
  24. Xiaobo Cheng · 1 shared paper, 2020 · strength 0.11
  25. Hanxing Tong · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.